Publish in this journal
Journal Information
Vol. 60. Issue 3.
Pages 285-293 (March 2007)
Vol. 60. Issue 3.
Pages 285-293 (March 2007)
Full text access
Diagnosis, Management and Treatment of Chronic Chagas' Heart Disease in Areas Where Trypanosoma cruzi Infection Is Not Endemic
Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica
Joaquim Gascóna, Pedro Albajarb, Elías Cañasc, María Floresd, Jordi Gómez i Prate, Ramón N Herreraf, Carlos A Lafuenteg, Héctor L Luciardif, Álvaro Moncayoh, Lluís Molinai, José Muñoza, Sabino Puentej, Ginés Sanzk, Begoña Treviñoe, Xavier Sergio-Sallesl
a Secció Medicina Tropical-Centre Salut Internacional, IDIBAPS, Hospital Clínic, Barcelona, España,
b Departamento de Medicina Tropical, Instituto Oswaldo Cruz-Fiocruz, Río de Janeiro, Brasil,
c Consulta Salud Internacional, Hospital Universitario Virgen del Rocío, Sevilla, España,
d Servicio de Parasitología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, España,
e Unitat de Medicina Tropical i Salut Internacional Drassanes, ICS, Barcelona, España,
f Facultad de Medicina, Universidad Nacional de Tucumán, Tucumán, Argentina,
g Medicina Tropical, Hospital Japonés, Santa Cruz, Bolivia,
h Universidad de los Andes, Bogotá, Colombia,
i Servicio de Cardiología, Hospital del Mar, Barcelona, España,
j Sección de Medicina Tropical, Hospital Carlos III, Madrid, España,
k Centro Nacional de Investigaciones Cardiovasculares, Madrid, España,
l Fundaçao Oswaldo Cruz, IPEC, UFRJ, HUCFF, Río de Janeiro, Brasil,
Ver más
This item has received
Article information
Full Text
Download PDF
Tables (5)
TABLE 1. Signs and Symptoms Most Frequently Associated With Heart Disease Due to T cruzi
TABLE 2. Most Common Electrocardiographic Abnormalities in Chagas' Heart Disease
TABLE 3. Most Common Echocardiographic Findings in Chagas' Heart Disease
TABLE 4. Rate of Moderate or Severe Left Ventricular Dysfunction (Ejection Fraction
TABLE 5. Summary of the Main Indications for Diagnostic Tests in Chagas' Heart Disease
Show moreShow less
La enfermedad de Chagas o tripanosomiasis americana es una parasitosis originaria del continente americano. En la naturaleza, Trypanosoma cruzi se transmite vectorialmente a través de diversas especies de chinches triatominos. No obstante, se han descrito otros mecanismos de transmisión no vectorial, como la transmisión a través de productos sanguíneos o mediante el trasplante de órganos infectados, y la transmisión vertical. Actualmente, la enfermedad de Chagas afecta a unos 10-12 millones de personas en el mundo y el proceso de urbanización en América Latina y los movimientos migratorios desde los países endémicos han posibilitado que la enfermedad de Chagas sea diagnosticada en zonas donde la infección no es endémica. Se considera que un 20-30% de las personas infectadas por T. cruzi desarrollarán a lo largo de su vida alteraciones cardiacas. Las características diferenciales de la cardiopatía chagásica, el escaso conocimiento que se tiene de ella en nuestro medio y la elevada frecuencia de arritmias y muerte súbita como primeras manifestaciones potenciales de esta enfermedad hacen prioritarias la elaboración y divulgación de protocolos diagnósticos y terapéuticos para la atención de estos pacientes a fin de mejorar el conocimiento de esta patología por los profesionales sanitarios potencialmente implicados en su detección y manejo.
Palabras clave:
Enfermedad de Chagas
Muerte súbita
Chagas' disease, or American trypanosomiasis, is a parasitic zoonosis found only in the Americas. Under natural conditions, Trypanosoma cruzi is transmitted by insects belonging to different species of Triatoma. However, several routes of transmission that do not involve insect vectors have also been described, such as transmission via blood products or transplantation of infected organs, and vertical transmission. At present, the number of people infected with Chagas' disease worldwide is estimated to be about 10-12 million. The process of urbanization in Latin America and migratory population movements from endemic countries have led to the disease being diagnosed in non-endemic areas. It is estimated that 20-30% of individuals infected with T. cruzi will develop symptomatic heart disease at some point during their lives. The specific differential characteristics of chronic chagasic cardiopathy, lack of knowledge of the disease among many healthcare workers, and the fact that arrhythmia or sudden death is frequently the first manifestation of disease all make it essential that diagnostic and therapeutic protocols for the disease are developed and disseminated. The aim should be to improve patient care by increasing understanding of the condition by physicians and other healthcare professionals who may be involved in its detection and treatment.
Chagas' disease
Heart disease
Sudden death
Full Text


Chagas' disease or American trypanosomiasis is a parasitosis originating on the American continent. Carlos Chagas described the disease at the beginning of the 20th century and it continues to represent one of the most significant public health challenges in Latin America.

The epidemiologic trends in the last 20 years clearly reveal a general reduction in vector transmission due to control programs and improvements in rural housing, as well as the interruption of vector transmission in Chile, Uruguay, and recently, Brazil, all of which has contributed to a reduction in the incidence of the disease throughout the continent.1-3

In the natural environment, Trypanosoma cruzi is transmitted through a variety of species of triatomine bugs, which act as vectors. However, other nonvector transmission mechanisms have been described via blood products, organ transplant, and vertical transmission. In regions where infection is endemic, oral transmission has also been described through ingestion of food contaminated with feces from infected bugs.4,5

Currently, Chagas' disease affects 10 to 12 million individuals worldwide.6 Its geographic distribution extends from the 40th parallel north, in the southern part of North America, to 45th parallel south, in Argentina and Chile.7 Latin American urbanization, which intensified in the second half of the 20th century, has altered the epidemiologic profile of the disease, and migratory movements from endemic countries have led to the diagnosis of Chagas' disease in regions in which it is not endemic.8,9

Spain has become one of the European countries that receive the largest number of immigrants from Latin American. As of December 31, 2005 close to a million individuals from Latin America were included in the records of foreign nationals holding a Spanish resident's identity card,10 although municipal census records for the year 2005 indicated higher figures (1 445 796 individuals). Units and services specialized in tropical medicine and international health in Spain have already begun to diagnose and treat individuals with the disease.11

The recent meeting of the Pan-American Health Organization in Montevideo discussed this situation and in its final report mentioned the needs of countries receiving immigrants from endemic areas in order to deal with Chagas' disease and to be able to provide appropriate treatment to affected individuals, as well as to prevent vertical and bloodborne transmission of T cruzi.12


Following the acute phase of the infection, untreated Chagas' disease enters a chronic phase that is initially asymptomatic or unrecognized. Subsequently, 20%-30% of patients develop cardiac abnormalities (cardiac form), 10% digestive complaints (digestive form) or both (mixed form), and less than 5% of patients develop a neurologic form of the disease. The remainder will remain asymptomatic, with no clinical manifestations throughout their lifetime.13

Due to the potential severity of the cardiac complications of the disease and their frequency, the second workshop on imported Chagas' disease focused on the clinical characteristics of chronic Chagas' heart disease and the requirements for correct diagnosis, management, and treatment. The pathogenesis of the disease is not clear, although current understanding points towards a mixed etiology, in which the parasite would be directly involved in producing myocardial damage14,15 and an associated autoimmune phenomenon.16,17 Other described pathogenic mechanisms include microvascular alterations and autonomic denervation.18-21

Chagas' heart disease displays certain characteristics that differentiate it from other cardiac conditions more commonly seen in Spain:

­ It is a fibrotic disease that is generally located in the posteroinferior and apical region of the left ventricle, the sinus node, and the conduction system below the bundle branch, and it leads to predominantly segmental abnormalities in contractility

­ It is a dilated cardiomyopathy with a tendency towards the formation of aneurysms, particularly in the apical region

­ It has powerful arrhythmogenic potential and ventricular arrhythmias are common, often associated with bradyarrhythmias (atrioventricular in origin or arising in the sinus node)

­ It is associated with a high rate of thromboembolic events

­ It can present as precordial pain, generally atypical although it can occasionally mimic ischemic heart disease.

In the natural course of the disease, the cardiac abnormalities appear progressively around 20 to 30 years following infection.22 However, 5% to 10% of patients display myocarditis during the acute phase that progresses rapidly towards a severe form of Chagas' heart disease.23,24 Less commonly, patients who are in the chronic phase of the disease, with mild cardiac involvement, can display sudden exacerbation with intense parasitemia and symptoms of acute heart failure; immunosuppressants also favor these exacerbations.25


Diagnosis of T cruzi Infection

Diagnosis of Chagas' disease in Spain was addressed in the consensus document from the first workshop on imported Chagas' disease.26 In summary, it is based on 2 criteria being met:

­ History compatible with the epidemiology of the disease: the patient's history should include at least 1 element that would have made transmission of T cruzi possible via any of the described routes of infection (individuals from endemic zones or children of mothers from endemic zones; travelers with stays in endemic regions and with a lifestyle that puts them at risk of infection)

­ Microbiologic diagnosis: individuals are considered to be infected when they have a positive result in parasitology or 2 positive results with 2 serologic techniques that employ different antigens. In the case of ambiguous or inconsistent results, a third technique should be used. There are various serologic tests for diagnosis of Chagas' disease that use different techniques (enzyme-linked immunosorbent assay [ELISA], modified ELISA or ELISA with recombinant antigens, immunofluorescence, indirect hemagglutination, and immunochromatography). Polymerase chain reaction (PCR) is perhaps the most sensitive technique for parasitologic analysis of chronic Chagas' disease, but its use does not remove the need for serologic testing

Basic Cardiac Examination in Patients With T cruzi Infection

To rule out cardiac involvement in patients with T cruzi infection, a full history and complete physical examination should be performed along with electrocardiography, chest radiography, and echocardiography. The symptoms and signs of Chagas' heart disease seen on physical examination are the same as for cardiomyopathy in general and none are characteristic of the disease.

Medical History

The main aim of the history is to detect symptoms of possible underlying heart disease. Table 1 shows the signs and symptoms that are most often associated with heart disease due to T cruzi. It is also important to assess digestive disorders (dysphagia, constipation, etc), since both forms can sometimes coexist.

When the patient history is taken, it is important to remember that linguistic and cultural differences can interfere with communication between patient and doctor. Occasionally, patients do not apply the same meaning to particular words (for instance, terms used in Spanish for breathlessness [ahogo], dizziness [mareo], or palpitations [palpitaciones]) and it may be necessary to define what is referred to in each case. In addition, immigrants often suffer difficulties in adaptation, homesickness, and mood disorders relating to their social and family situation27 that can cause problems in accurately identifying the cardinal symptom or reason for consultation. Finally, unfavorable working conditions must also be taken into account (long working hours, fear of losing a job, illegal contracts, etc) as they represent an additional obstacle to attending scheduled appointments. Since the disease is familiar to these patients and causes them to worry, notification of a positive result for infection or Chagas' disease requires a careful communication process through which trust is built.12 Cultural mediators play an important role in this process.

Physical Examination

A detailed physical examination should be performed with particular attention to the cardiovascular system. Cardiac murmurs due to valvular dysfunction can appear as a result of dilation of the chambers. In more advanced stages, the usual signs of congestion and peripheral hypoperfusion are observed. Cardiac cachexia is also an indicator of more advanced stages of Chagas' heart disease and has a high prognostic value.


A conventional 12-lead electrocardiogram (ECG) with a long recording (30 seconds) in DII should be performed in all patients with T cruzi infection. In the chronic phase of the infection, ECG alterations appear a number of years before symptoms and cardiomegaly (Table 2). Although there is no characteristic pattern in the ECG, these changes, especially right bundle-branch block, in isolation or associated with left anterior hemiblock in patients with positive serology, can be considered indicators of chronic Chagas' heart disease.28-30 Nevertheless, given their lack of specificity, the diagnosis requires confirmation, since its presence does not necessarily signify Chagasic etiology.

A normal ECG rules out the presence of moderate or severe left ventricular dysfunction, with a negative predictive value of close to 100%: On the other hand, the greater the number of ECG changes, the worse the ventricular function.31

Alterations in intraventricular conduction and widening of the QRS complex appear early in chronic Chagas' heart disease, when abnormalities in myocardial contraction are not yet present, meaning that they lack the prognostic value that they display in other heart disease.32

Chest Radiography

Chest radiography has a low sensitivity for the detection of Chagas' heart disease, since ventricular dysfunction can occur while still obtaining a normal radiograph. However, evidence of cardiomegaly could be predictive of sudden death in patients with chronic Chagas' disease.33 It should be performed with the patient in a clinically compensated situation, assessing venous-capillary hypertension, expansion of the chambers, or a cardiothoracic index of more than 0.6 as positive signs.


Given that echocardiography is a widely available noninvasive technique that is very useful for assessment of ventricular function, all patients with Chagas' disease are candidates for a baseline echocardiogram.

The most common echocardiographic alterations are summarized in Table 3.34,35 The following recommendations are useful for echocardiography:

It is advisable to perform a conventional transthoracic echocardiography examination, following a specific system.

1. Use a high-frequency transducer.

2. Obtain a transverse echocardiogram (for segmental analysis of the inferoposterior region), an apical 2-chamber view, and intermediate views between 2 and 4 chambers, to detect possible apical aneurysms.

3. Particular attention should be paid to the posteroinferior region of the left ventricle, including the cardiac apex, in an effort to identify segmental hypokinesia or akinesia, along with apical aneurysms. It is also common to observe hyperechogenicity and wall shrinkage, similar to that described in ischemic heart disease; this is a substrate for the development of reentrant ventricular arrhythmias.

4. It is recommended that particular attention be paid to the search for spontaneous echo contrast and the existence of thrombi in the chambers.

5. Specifically assess diastolic function and right ventricular function in all patients with suspected Chagas' heart disease. Alteration of left ventricular diastolic function occurs early in Chagas' disease and its severity is usually correlated with the degree of systolic dysfunction.36,37

6. Transesophageal examination is indicated when the transthoracic window does not allow assessment of the left chambers.

Reduction of left ventricular ejection fraction, increased end-systolic diameter, and a restrictive mitral flow pattern are the best prognostic indicators obtained by echocardiography in patients with Chagas' heart disease.38,39

In advanced stages of the disease, when congestive heart failure is present, the predominant echocardiographic profile involves diffuse biventricular hypokinesia with enlargement of all 4 chambers.

Other Cardiologic Examinations in Patients With Suspected Chagas' Heart Disease

In addition to the basic studies mentioned, other complementary examinations may be useful in certain patients or circumstances:

24-Hour Holter Monitoring

Twenty-four hour Holter monitoring is recommended in patients with the following symptoms:

­ Symptoms suggestive of cardiac arrhythmia (syncope, presyncope, or palpitations)

­ The presence of certain cardiac arrhythmias in the ECG, such as sinus bradyarrhythmias (with a mean heart rate of less than 40 beats per minute and/or prolonged sinus pauses), second degree atrioventricular blocks, and frequent and/or repetitive (bursts) ventricular extrasystoles

Twenty-four hour Holter monitoring will allow assessment of the possible association of symptoms with an arrhythmia, identification of patients at risk of sudden death, and identification of autonomic dysfunction.33,40 Episodes of nonsustained ventricular tachycardia are recorded in approximately 90% of patients with Chagas' heart disease and ventricular dysfunction or heart failure.41

Holter monitoring should be performed using a conventional technique, preferably with a 3-channel system. The sensitivity of Holter recording is low when episodes of arrhythmia are infrequent and other techniques such as implantable Holter can be used in these cases.

Electrophysiology Study

The aim of an electrophysiologic study in these patients is to identify atrioventricular and intraventricular conduction abnormalities and to assess induction of malignant ventricular arrhythmias. The indications are the same as for assessment of other disorders with a risk of sudden death:

­ Patients with symptoms suggestive of arrhythmia (syncope or presyncope) not confirmed in previous studies

­ Sustained ventricular tachycardia, with or without symptoms, irrespective of the degree of ventricular function

­ Patient resuscitated from sudden death

­ Patients who display alterations in the ECG or Holter monitoring that are associated with increased risk of sudden death: repeated or paired ventricular extrasystoles, episodes of nonsustained ventricular tachycardia, and increased spread of the QT interval associated with the presence of ventricular dysfunction.42 In this subset of patients, if an electrophysiologic study is not possible, amiodarone can be administered empirically so long as there are no contraindications.

Exercise Testing

Exercise testing would mainly be indicated in the following cases:

­ Assessment of functional capacity

­ Assessment of the chronotropic response

In the presence of chest pain and Chagas' heart disease, exercise testing is of little use in determining the etiology of the pain; in those cases coronary angiography should be performed

Coronary Angiography

Coronary angiography is indicated according to the criteria of the Spanish Society of Cardiology,43 taking into account the considerations regarding exercise testing.

Myocardial Biopsy

Myocardial biopsy is not currently considered a diagnostic technique in Chagas' heart disease as a result of its risk and limited specificity.


Asymptomatic Patients With Normal Electrocardiogram and Chest Radiograph

The risk of Chagas' heart disease is greater during the second and third decades following infection.44 In patients with evidence of T cruzi infection and with normal ECG or minimal abnormalities that are not suggestive of chronic Chagas' heart disease, the annual risk of progression to heart disease is between 2% and 5%.45,46 As a result, baseline echocardiogram is recommended.

Asymptomatic Patients With ECG Abnormalities

Baseline echocardiography is recommended in asymptomatic patients with ECG abnormalities. The findings are highly variable, and left ventricular dysfunction (ejection fraction less than 40%) is detected in approximately 30% of cases. Table 4 shows the prevalence of left ventricular dysfunction according to ECG pattern.47 In general, prognosis is determined by the degree of ventricular dysfunction.48

The frequency with which echocardiography should be repeated will depend on the clinical condition of the patient. Although studies are unavailable, progression of the disease is slow in asymptomatic patients with a normal echocardiogram; consequently, it is sufficient to repeat the assessment within the following 5 years in this group, so long as symptoms do not appear. When the initial study reveals abnormalities it should be repeated in a period of 1 to 3 years, due to the increased risk of progression,49 especially if there is significant ventricular dysfunction (ejection fraction less than 40%). In any patient, the appearance of new symptoms or ECG abnormalities should be considered an indication for a new echocardiogram.

The purpose of echocardiographic follow-up is to identify patients with moderate or severe dysfunction, who are often still asymptomatic but who could benefit from the early provision of drugs for the management of heart disease.50

Symptomatic Patients

Patients with symptomatic Chagas' heart disease (Table 1) should be considered to be at increased risk of sudden death. Such nonspecific symptoms as weakness or wobbliness have much more significance in this context as they could be predictive of an episode of syncope. It is important to remember that sudden death can often be the first manifestation of Chagas' heart disease.51,52 Table 5 summarizes the main indications for diagnostic tests in assessment of Chagas' heart disease.


Management of Ventricular Dysfunction and Heart Failure

In general, the management of these patients has much in common with that of other heart disease. It should also be taken into account that general measures are often applied to Chagas' heart disease that are not specifically validated for use in this disease. β-blockers (with the precautions mentioned in the following paragraph) and angiotensin converting enzyme inhibitors (ACEI) are the recommended drugs for use in patients with moderate or severe ventricular dysfunction (ejection fraction <40%). Despite the absence of scientific evidence of its beneficial effect, amiodarone is used in these patients due to the presence of complex arrhythmias.53

There are peculiarities in Chagas' heart disease that are important to take into consideration for the therapeutic management of these patients:

­ Chronic Chagas' heart disease is associated with a high rate of bradyarrhythmias (atrioventricular block, sinus node dysfunction, etc). Consequently, drugs such as digitalis glycosides, β-blockers, some calcium channel antagonists, and amiodarone should be used with care, initiating treatment at low doses and carefully monitoring the possible appearance of complications

­ Patients with refractory heart failure can be assessed as candidates for heart transplant. Despite the description of some cases of reactivation of Chagas' disease, published case series show satisfactory results and improved survival in these patients compared to patients with ischemic heart disease or idiopathic dilated cardiomyopathy54

­ There is no indication for cardiomyoplasty or reconstructive surgery in this disease

­ The usefulness of resynchronization therapy in these patients is still under discussion and echocardiographic and ECG criteria should be used to assess its indication

­ Some preliminary unpublished results have been obtained on improvement of myocardial function through the use of stem cells in patients with Chagas' disease

Management and Prevention of Thromboembolism

The high rate of thrombotic and embolic events should be taken into consideration in patients with Chagas' disease. Most of these events are cerebral ischemic accidents and many patients present cardiovascular causes that account for the phenomenon, although there are other factors involved.55,56

In a study performed in Brazil, 4 predictors of embolic cerebrovascular accident were identified in patients with underlying Chagas' heart disease: age above 48 years, primary abnormality in ventricular repolarization, apical aneurysm, and left ventricular ejection fraction of less than 50%.57 The presence of these 4 predictors was associated with an annual incidence of cerebrovascular accident of 4%. In the absence of more definitive evidence, prevention of thromboembolism in patients with chronic Chagas' heart disease should nevertheless be guided by standard clinical recommendations: patients with atrial fibrillation, prior embolic events, and/or the existence of wall thrombi. The role of antiplatelet drugs in the prevention of thromboembolic events has yet to be determined.

Management of Bradyarrhythmias

Symptomatic bradyarrhythmias are sometimes candidates for implantation of a pacemaker. International guidelines on pacemaker implantation are useful in patients with Chagas' heart disease.

Management of Ventricular Arrhythmias

Patients with Chagas' heart disease often present ventricular extrasystoles and tachycardias, most commonly associated with myocardial damage that generates reentry phenomena. Most sustained ventricular tachyarrhythmias in patients with Chagas' heart disease do not arise from apical aneurysm of the left ventricle but rather from the inferolateral region.58,59

Since it involves progressive abnormality with multiple arrhythmogenic foci, radiofrequency ablation should not be considered a first choice technique.

In contrast, and despite the absence of specific studies in chronic Chagas' heart disease, implantation of an implantable cardioverter defibrillator is recommended to reduce the risk of sudden death in the following situations:

­ Sustained ventricular tachycardia. In addition, in these patients it is advised that amiodarone is administered empirically in an effort to reduce the rate of discharge and lower the likelihood of electrical storm. If the patient receives too many discharges despite this treatment, radiofrequency ablation should be considered60,61

­ Monomorphic sustained ventricular tachycardia during the electrophysiology study

Administration of amiodarone is a possibility in patients with nonsustained ventricular tachycardia and normal electrophysiologic study (noninducible).

Management of Angina Pain

Chest pain sometimes constitutes a clinical manifestation of Chagas' heart disease and even esophageal Chagas' disease. It is postulated that the pathophysiologic mechanism underlying this symptom is abnormal myocardial microvasculature.

If chest pain is the primary or predominant symptom of Chagas' heart disease, differential diagnosis should include assessment of associated ischemic heart disease by cardiac catheterization. Assessment of myocardial perfusion with techniques employing radioactive isotopes can be used, although their usefulness for differential diagnosis of angina pain is limited by the presence of areas of myocardial fibrosis in patients with Chagas' heart disease. No specific treatment is available for such cases.


It is known that in the chronic phase of the disease, the cure rate in adults ranges from 8% to 25%.62 The reduction in the titer of serum antibodies is used as a marker of cure, but the slow rate at which serologic changes occur, possible repeat infections in endemic areas, and the lack of clinical markers have made it difficult to clearly determine the efficacy of the treatment. Consequently, and as a result of the potential adverse effects of the medication, there is no international consensus on etiologic treatment in this phase of the disease. However, a recent study showed a reduction in the progression of Chagas' disease in patients treated with benznidazole.63 According to the 2005 consensus document,26 patients with positive parasitology tests should receive etiologic treatment and it should be considered for others; an agreement should be established between doctor and patient and adequate information on the potential adverse effects of the drug provided.


Chagas' disease should be suspected in all patients whose history is compatible with the epidemiology of the disease and who have symptoms of cardiac involvement. The differential characteristics of Chagas' heart disease, the limited information available on the disease in Spain, and the high rate of arrhythmias and sudden death as potential primary manifestations of the disease make it a priority to prepare and distribute diagnostic and treatment protocols for the care of these patients in order to improve the understanding of the disease by health professionals involved in its detection and management.

In some settings, the necessary techniques may not be available for correct diagnosis and treatment of patients with suspected Chagas' disease or Chagas' heart disease. If a patient with a history compatible with the epidemiology of the disease displays signs and symptoms of heart disease, it is recommended that the individual is referred to a specialist in cardiology and a hospital specialized in imported diseases. In both cases, referral should not imply that the primary care physician, who is responsible for the initial assessment of the patient, does not obtain a good medical history and perform a clinical assessment, conventional ECG, and chest radiography prior to referring the patient.

Clearly, the management of chronic Chagas' heart disease has been, and continues to be, a topic of scientific discussion in endemic countries. For further information, readers are directed to the consensus reports of the Argentinian Society of Cardiology and the Brazilian Society of Cardiology64,65; these documents are available in the internet.

The workshop on imported Chagas' disease took place on March 6 and 7, 2006 and was funded by Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2005/ARCS2/00040) of the Catalan Regional Government, the Spanish Ministry of Education and Science (SAF-200524601-E), and the Tropical Medicine Network of the Spanish Health Research Fund (RICET). Various individuals involved in the preparation of the consensus document participate in the RICET network and the Catalan Network for Epidemiologic Monitoring of Tropical and Imported Diseases (RIVEMTI).

Correspondence: Dr. J. Gascón.
Secció Medicina Tropical. Centre de Salut Internacional. Hospital Clínic.
Villarroel, 170. 08036 Barcelona. España.

Genève: OMS; 2003. p. 74, 75 y 92.
Moncayo A..
Current epidemiological trends after the interruption of vectorialnd transfusional tranmission of Chagas disease in the Southern Cone countries. Mem Inst Oswaldo Cruz, Rio de Janeiro, 58 (2003), pp. 577-91
Boletín de Vigilancia Semanal. La Paz, julio 2006. Available from:
Prata A..
Clinical and epidemiological aspects of Chagas disease..
Lancet Infect Dis, 1 (2001), pp. 92-100
Considerations on the epidemiology and transmisión of Chagas disease in the Brazilian Amazon. Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:395-8.
American trypanosomiasis and its impact on public health in the Americas. In: Brener Z, Andrade ZA, BarralNeto M, editors. Trypanosoma cruzi e Doença de Chagas. Rio de Janeiro: Guanabara Koogan; 2000. p. 1-20.
Hayes R, Schofield C..
Estimación de tasas de incidencia de infecciones y parasitosis crónica a partir de la prevalencia: la enfermedad de Chagas en América Latina..
Bol Ofic Sanit Panam, 108 (1990), pp. 308-16
Sztajzel J, Cox J, Pache JC, Badaoui E, Lerch R, Rutishauser W..
Chagas' disease may also be encountered in Europe..
Eur Heart J, 17 (1996), pp. 1289
Ueno Y, Nakamura Y, Inoue T, Endo S, Kinoshita M, Takeuchi T..
A highly suspected case of chronic Chagas'heart disease diagnosed in Japan..
Jpn Circ J, 59 (1995), pp. 219-23
Características clínicas de pacientes infectados por Trypanosoma cruzi. Enf Emerg. 2006;8 Suppl 1:42-4.
Baruch WA, Arribada JA, Bulla DH, Carlier Y, Rodrigues J, Chuit R, et al..
Consulta Técnica Regional OPS/MSF sobre Organização e estrutura da atenção médica do doente e infectado por Trypanosoma cruzi/doença de Chagas..
Rev Soc Bras Med Trop, 38 (2005), pp. 538-41
Dias JCP..
Natural history of Chagas' disease..
Arq Bras Cardiol, 65 (1995), pp. 359-66
Bellotti G, Bocchi EA, De Moraes AV, Higuchi ML, Barbero-Marcial M, Sosa E, et al..
In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease..
Am Heart J, 131 (1996), pp. 301-7
Higuchi ML, de Brito T, Reis MM, Barbosa A, Bellotti G, Pereira-Barreto AC, et al..
Correlation between Trypanosoma cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings..
Cardiovasc Pathol, 2 (1993), pp. 101-6
Takle GB, Hudson L..
Autoimmunity and Chagas' disease..
Curr Top Microbiol Immunol, 145 (1989), pp. 79-92
López L, Arai K, Jiménez E, Jiménez M, Pascuzo C, RodríguezBonfante C, et al..
C-Reactive Protein and Interleukin-6 serum levels increase as Chagas disease progreses towards cardiac failure..
Rev Esp Cardiol, 59 (2006), pp. 50-6
Rossi MA..
Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease..
Am Heart J, 120 (1990), pp. 233-6
Immunopathology of Chagas disease: a historical overview. Mem Inst Oswaldo Cruz. 1999;99 Suppl:247-8.
Marin-Neto JA..
Cardiac dysautonomia and pathogénesis of Chagas' heart disease..
Int J Cardiol, 66 (1998), pp. 129-31
Dávila-Spinetti DF, Colmenarez-Mendoza HL, Lobo-Vielma L..
Mecanismos causantes de la progresión del daño miocárdico en la enfermedad de Chagas crónica..
Rev Esp Cardiol, 58 (2005), pp. 1007-9
Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, Álvarez MG, et al..
Indicadores clínicos de progresión de la miocaditis chagásica crónica..
Rev Esp Cadiol, 58 (2005), pp. 1037-44
Chagas C..
Pathogenic processes of American trypanosomiasis..
Mem Inst Oswaldo Cruz, 8 (1916), pp. 3-38
Prata A..
Prognóstico e complicações da doença de Chagas..
Rev Goiana Med, 5 (1959), pp. 87-96
Simoes MV, Nonino A, Simoes BP, Almeida-Filho OC, Maciel BC, Marin-Neto JA..
Reagudization of Chagas myocarditis inducing exclusive right ventricular failure..
Arq Bras Cardiol, 62 (1994), pp. 435-7
Gascon J..
Diagnóstico y tratamiento de la enfermedad de Chagas importada. Documento de consenso..
Med Clin (Barc), 125 (2005), pp. 230-5
Achotegui J..
Emigration in hard conditions: the Immigrant Syndrome with chronic and multiple stress (Ulysses' Síndrome)..
Vertex, 16 (2005), pp. 105-13
Laranja FS, Dias E, Nobrega G, Miranda A..
Chagas' disease: a clinical, epidemiologic, and pathologic study..
Circulation, 14 (1956), pp. 1035-60
Maguire JH, Hoff R..
Cardiac morbidity and mortality due to Chagas disease: prospective eletrocardiographic study of a brazilian community..
Circulation, 75 (1987), pp. 1140-5
Dias JC.P, Kloetzel K..
The prognostic value of the electrocardiographic features of chronic Chagas'disease..
Rev Inst Med Trop São Paulo, 10 (1968), pp. 158-62
Sousa AS, Xavier SS, Pereira JB, Roy LO, Alvarenga G, Mallet AL.R, et al..
Predictive models of moderate or severe systolic dysfunction in Chagas' disease based on clinical, electrocardiographic and radiological data..
Rev Bras Eco, 14 (2001), pp. 63-71
Garcia MI, Sousa AS, Hasslocher-Moreno A, Mallet AL.R, Xavier SS..
Valor prognóstico da largura do QRS na cardiopatia chagásica crônica com disfunção ventricular moderada a grave..
Rev Bras Eco, 16 (2003), pp. 53-9
Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al..
Development and validation of a simple risk score for predicting mortality in Chagas'heart disease..
N Engl J Med, 355 (2006), pp. 799-808
Acquatella H, Schiller NB, Puigbó JJ, Suárez JA, Casal H..
M-mode and two-dimensional echocardiography in chronic Chagas' heart disease. A clinical and pathologic study..
Circulation, 62 (1980), pp. 787-99
Xavier SS, Hasslocher-Moreno A, Pirmes C, Borges J, Barroso J, Barroso PF..
Echocardiographic features of chronic Chagas' Herat diseases..
J Am Coll Cardiol, 29 (1997), pp. 223A
Siciliano APR.V, Hasslocher-Moreno A, Sousa AS, Brasil PEA.A, Holanda MT, Garcia MI, et al..
Padrão da função diastólica e relação com a gravidade da forma clínica em 902 pacientes na fase crónica da enfermedad de Chagas..
Rev Socerj, 19 (2006), pp. 75-84
Combellas I, Puigbo JJ, Acquatella H, Tortoledo F, Gomez JR..
Echocardiographic features of impaired left ventricular diastolic function in Chagas's heart disease..
Br Heart J, 53 (1985), pp. 298-309
Xavier SS, Sousa AS, Alencar AT, Borges-Pereira J, HasslocherMoreno A..
Nova proposta de classificação do acometimento cardíaco na fase crônica da doença de Chagas com uso do ecocardiograma..
Rev Bras Eco, 13 (2000), pp. 3
Nunes MC.P, Barbosa MM, Rocha MOC..
Valor prognostico da disfunção diastólica em pacientes com miocardiopatia dilatada chagásica..
Rev Bras Eco, 17 (2004), pp. 15-22
Ribeiro AL.P, Lombardi F, Sousa MR, Barros MV.L, Porta A, Barros VC.V, et al..
Power-law behavior of heart rate variability in Chagas' disease..
Am J Cardiol, 89 (2002), pp. 414-8
Frequência e grau de extra-sistolia ventricular à eletrocardiografia dinâmica (sistema Holter de 24 horas) na doença de Chagas. Arq Bras Cardiol. 1991;57 Suppl C:C134.
Salles G, Xavier SS, Sousa AS, Hasslocher-Moreno A, Cardoso C..
Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease. Results of a long-term follow-up study..
Espulgas E, Alfonso F, Alonso JJ, Asín E, Elizaga J, Iñiguez A, et al..
Guías de práctica clínica de la Sociedad Española de Cardiología en cardiología intervencionista: angioplastia coronaria y otras técnicas..
Rev Esp Cardiol, 53 (2000), pp. 218-40
Espinosa R, Pericci L, Carrasco HA, Escalante A, Martínez O, González R..
Prognostic indicators in chronic chagasic cardiopathy..
Int J Cardiol, 30 (1991), pp. 195-202
Macedo V..
Forma indeterminada da doença de Chagas..
J Bras Med, 38 (1980), pp. 34-40
Dias JC..
The indeterminate form of human chronic Chagas' disease. A clinical epidemiological review..
Rec Soc Bras Med Trop, 22 (1989), pp. 147-56
Modelos preditivos de disfunção moderada ou grave na enfermedad de Chagas, baseados em dados clínicos, eletrocardiográficos e radiológicos. Tese de Mestrado. Faculdade de Medicina, UFRJ, Rio de Janeiro. 2000.
Xavier SS, Sousa AS, Hasslocher-Moreno A..
Aplicação da nova classificação da insuficiencia cardiaca (ACC/AHA) na cardiopatia chagásica crónica: Análise crítica das curvas de sobrevida..
Rev Socerj, 18 (2005), pp. 227-32
Progressão da lesão miocardica na doença de Chagas: um estudo ecocardioográfico. Arq Bras Cardiol. 2004;83 Suppl 3:127.
The SOLVD Investigators..
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection..
N Engl J Med, 327 (1992), pp. 685-91
Prata A, Lopes ER, Chapadeiro E..
Características da morte súbita tida como não esperada na doença de Chagas..
Rev Soc Bras Med Trop, 19 (1986), pp. 9-12
Rassi A Jr, Rassi SG, Rassi A..
Sudden death in Chagas' disease..
Arq Bras Cardiol, 76 (2001), pp. 75-96
Chiale PA, Halpern MS, Nau GJ, Tambussi AM, Przybylski J, Lázzari JO, et al..
Efficacy of amiodarone during long term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis..
Am Heart J, 107 (1984), pp. 656-65
Bocchi EA, Bellotti G, Mocelin AO, Uip D, Bacal F, Higuchi ML, et al..
Heart transplantation for chronic Chagas' heart disease..
Ann Thorac Surg, 61 (1996), pp. 1727-33
Herrera RN, Díaz E, Pérez R, Chaín S, Sant-Yacumo Rodriguez E, Bianchi J, et al..
Estado protrombóitico en estadios tempranos de la enfermedad de Chagas crónica..
Rev Esp Cardiol, 56 (2003), pp. 377-82
Oliveira J, Correa de Araujo R, Navarro M, Muccillo G..
Cardiac trombosis and thromboembolism in chronic Chagas' disease. Am J Cardiol, 52 (1983), pp. 147-51
Estratégias de prevenção do acidente vascular encefálico cardioembólico na doença de Chagas. Arq Bras Cardiol. 2006. En prensa.
Oliveira JS, Mello de Oliveira JA, Frederigue U Jr, Lima Filho EC..
Apical aneurysm of Chagas' heart disease..
Br Heart J, 46 (1981), pp. 432-7
Sarabanda A, Sosa E, Scanavacca M, Magalhäes L, Kuniyoshi R, Darrieux F, et al..
Correlação entre a morfologia da taquicardia ventricular sustentada e a ventriculografia esquerda na cardiopatia chagásica crônica..
Rev Bras Marcapasso e Arritmias, 7 (1994), pp. 143
Sosa E, Scalabrini A, Rati M, Bellotti G, Pileggi F..
Successful catheter ablation of the «origin» of recurrent ventricular tachycardia in chronic chagasic heart disease..
J Electrophysiol, 1 (1987), pp. 5861
Sosa E, Scanavacca M, D'Avila A, Bellotti G, Pilleggi F..
Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic chagasic heart disease.Pace, 22 (1999), pp. 128-30
Ferreira HO..
Tratamento da forma indeterminada da doença de Chagas com Nifurtimox e benznidazol..
Rev Soc Bras Med Trop, 23 (1990), pp. 209-11
Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Álvarez MG, et al..
Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment..
Ann Int Med, 144 (2006), pp. 724-34
Rev Argent Cardiol. 2002;70 Suppl 1:9-86 [accedido 1 Dic 2006]. Available from:
Rev Soc Bras Med Trop. 2005;38 Suppl 3:7-29 [acceded 1/12/06]. Available from:
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?